ClinicalTrials.gg
CompletedNCT04779177Updated Nov 12, 2025Results posted

Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder

A Phase 1 interventional study of Lumateperone 42 mg and Lumateperone 28 mg in Schizophrenia and Pediatric, sponsored by Intra-Cellular Therapies, Inc.. Completed at 3 sites in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-11-12.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing lumateperone in Schizophrenia — 3 open to participants now, 3 under way, 2 of them phase 3. lumateperone · Schizophrenia.

Enrollment
10th of 12
26 · median 66
Started
2021
with 1 other
Phase 1
3 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
9 of 12
Intra-Cellular Therapies, Inc.

Among the 12 studies testing lumateperone in Schizophrenia, this one is the 10th largest by enrollment, is one of 2 that started in 2021, is one of 3 in phase 1, and was the 7th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 12 studies testing lumateperone in Schizophrenia are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lumateperone

lumateperone: first FDA approval 2019 (CAPLYTA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing lumateperone in Schizophrenia, or all of them as a file.
02

Study summary

Study ITI-007-020 is a Phase 1b, multicenter, open-label study to evaluate the safety, tolerability, and PK of lumateperone as treatment for adolescent patients with schizophrenia or schizoaffective disorder.

03

Conditions studied

  • Schizophrenia
  • Pediatric

Browse trials for

04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Male or female patients between 13 and 17 years of age, inclusive
  • Clinical diagnosis of schizophrenia or schizoaffective disorder according to (DSM-5)
  • Free from acute exacerbation of their psychosis for at least 3 months prior to Screening
  • Clinical Global Impression - Severity (CGI-S) score ≤ 4
  • (BMI) within 2 standard deviations of, age- and gender-specific body measurements (based on CDC Clinical Growth Chart, 2000)
  • Ability to swallow capsules

Main Exclusion Criteria:

  • Has a primary psychiatric diagnosis other than schizophrenia or schizoaffective disorder
  • Reports having experienced suicidal ideation within 6 months prior to Screening, any suicidal behavior within 2 years prior to Screening based on the Columbia-Suicide Severity Rating Scale (C-SSRS), and/or the investigator assesses the patient to be a safety risk to him/herself or others
  • abnormality within 2 years of Screening that in the Investigator's opinion may place the patient at risk or interfere with study outcome variables
  • History of a clinically significant cardiac disorder and/or abnormal screening (ECG) or a corrected for heart rate using Fridericia formula > 450 msec in males or > 470 msec in females
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Lumateperone 42 mg once daily for 5 days

    Drug: Lumateperone 42 mg

  • Experimental
    Lumateperone 28 mg once daily for 5 days

    Drug: Lumateperone 28 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Cmax

    Maximum plasma concentration of lumateperone

    Time frame: Day 1 and Day 5

  2. Pharmacokinetics: Tmax

    Time of maximum concentration of lumateperone in plasma

    Time frame: Day 1 and Day 5

  3. Pharmacokinetics: AUC0-t

    Area under the plasma concentration time curve from time zero to the last measurable of concentration of lumateperone

    Time frame: 0 to 24 hours post-dose on Day 1 and Day 5

  4. Pharmacokinetics: AUC0-tau

    Area under the plasma lumateperone concentration time curve from time zero to the end of dosing (tau)

    Time frame: 0 to 24 hours post-dose on Day 1 and Day 5

  5. Pharmacokinetics: t1/2

    Terminal elimination half-life of lumateperone

    Time frame: Day 1 and Day 5

  6. Pharmacokinetics: CL/F

    Apparent oral clearance of lumateperone

    Time frame: Day 1 and Day 5

Secondary outcomes

  1. Percentage of Subjects With Treatment-emergent Adverse Events

    Time frame: up to 30 days after last dose, up to a total of 35 days

  2. Change From Baseline in Systolic and Diastolic Blood Pressure

    Time frame: Baseline and Day 6

  3. Change From Baseline in ECG QT Interval

    QTcF

    Time frame: Baseline and Day 6

  4. Change From Baseline in Hemoglobin

    Time frame: Baseline and Day 6

  5. Change From Baseline in White Blood Cell Count

    Time frame: Baseline and Day 6

  6. Change From Baseline in Aspartate Aminotransferase

    Time frame: Baseline and Day 6

  7. Change From Baseline in Alanine Aminotransferase

    Time frame: Baseline and Day 6

  8. Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)

    AIMS is a measure of facial and oral movements, extremity movements and trunk movements. The AIMS total score is reported based on 7 items (items 1 through 7). Each item is rated on a scale from none (0) to severe (4). The AIMS total score ranges from 0 to 28. Higher values of total AIMS score indicate increased severity in abnormal movement.

    Time frame: Baseline and Day 6

07

Results

Posted Nov 12, 2025

Participant flow

Participant flow — Overall Study
MilestoneLumateperone 42 mg Once Daily for 5 Days
Started26
Completed21
Not completed5

Outcome measures

PrimaryPharmacokinetics: Cmax

Maximum plasma concentration of lumateperone

Time frame:
Day 1 and Day 5
Reported as:
Mean · ng/mL
Pharmacokinetics: Cmax
ng/mLLumateperone 42 mg Once Daily for 5 Days
Day 119.12 ± 11.21
Day 523.22 ± 12.60
PrimaryPharmacokinetics: Tmax

Time of maximum concentration of lumateperone in plasma

Time frame:
Day 1 and Day 5
Reported as:
Median · h
Pharmacokinetics: Tmax
hLumateperone 42 mg Once Daily for 5 Days
Day 11.000 (0.25 to 6.00)
Day 51.000 (0.50 to 4.00)
PrimaryPharmacokinetics: AUC0-t

Area under the plasma concentration time curve from time zero to the last measurable of concentration of lumateperone

Time frame:
0 to 24 hours post-dose on Day 1 and Day 5
Reported as:
Mean · h*ng/mL
Pharmacokinetics: AUC0-t
h*ng/mLLumateperone 42 mg Once Daily for 5 Days
Day 143.612 ± 21.404
Day 554.975 ± 26.992
PrimaryPharmacokinetics: AUC0-tau

Area under the plasma lumateperone concentration time curve from time zero to the end of dosing (tau)

Time frame:
0 to 24 hours post-dose on Day 1 and Day 5
Reported as:
Mean · h*ng/mL
Pharmacokinetics: AUC0-tau
h*ng/mLLumateperone 42 mg Once Daily for 5 Days
Day 148.158 ± 20.899
Day 558.437 ± 27.792
PrimaryPharmacokinetics: t1/2

Terminal elimination half-life of lumateperone

Time frame:
Day 1 and Day 5
Reported as:
Mean · h
Pharmacokinetics: t1/2
hLumateperone 42 mg Once Daily for 5 Days
Day 12.208 ± 0.6162
Day 52.681 ± 1.092
PrimaryPharmacokinetics: CL/F

Apparent oral clearance of lumateperone

Time frame:
Day 1 and Day 5
Reported as:
Mean · L/h
Pharmacokinetics: CL/F
L/hLumateperone 42 mg Once Daily for 5 Days
Day 13062.0 ± 1292.0
Day 5947.14 ± 595.34
SecondaryPercentage of Subjects With Treatment-emergent Adverse Events
Time frame:
up to 30 days after last dose, up to a total of 35 days
Reported as:
Count of participants · Participants
Percentage of Subjects With Treatment-emergent Adverse Events
ParticipantsLumateperone 42 mg Once Daily for 5 Days
Percentage of Subjects With Treatment-emergent Adverse Events16
SecondaryChange From Baseline in Systolic and Diastolic Blood Pressure
Time frame:
Baseline and Day 6
Reported as:
Mean · mmHg
Change From Baseline in Systolic and Diastolic Blood Pressure
mmHgLumateperone 42 mg Once Daily for 5 Days
Supine Systolic Blood Pressure0.7 ± 10.74
Diastolic Systolic Blood Pressure-0.5 ± 6.64
SecondaryChange From Baseline in ECG QT Interval

QTcF

Time frame:
Baseline and Day 6
Reported as:
Mean · msec
Change From Baseline in ECG QT Interval
msecLumateperone 42 mg Once Daily for 5 Days
Change From Baseline in ECG QT Interval-3.4 ± 15.19
SecondaryChange From Baseline in Hemoglobin
Time frame:
Baseline and Day 6
Reported as:
Mean · g/dL
Change From Baseline in Hemoglobin
g/dLLumateperone 42 mg Once Daily for 5 Days
Change From Baseline in Hemoglobin-0.50 ± 0.959
SecondaryChange From Baseline in White Blood Cell Count
Time frame:
Baseline and Day 6
Reported as:
Mean · cells*10^9/L
Change From Baseline in White Blood Cell Count
cells*10^9/LLumateperone 42 mg Once Daily for 5 Days
Change From Baseline in White Blood Cell Count-0.24 ± 1.173
SecondaryChange From Baseline in Aspartate Aminotransferase
Time frame:
Baseline and Day 6
Reported as:
Mean · U/L
Change From Baseline in Aspartate Aminotransferase
U/LLumateperone 42 mg Once Daily for 5 Days
Change From Baseline in Aspartate Aminotransferase-4.0 ± 2.78
SecondaryChange From Baseline in Alanine Aminotransferase
Time frame:
Baseline and Day 6
Reported as:
Mean · U/L
Change From Baseline in Alanine Aminotransferase
U/LLumateperone 42 mg Once Daily for 5 Days
Change From Baseline in Alanine Aminotransferase-3.2 ± 2.81
SecondaryChange From Baseline in Abnormal Involuntary Movement Scale (AIMS)

AIMS is a measure of facial and oral movements, extremity movements and trunk movements. The AIMS total score is reported based on 7 items (items 1 through 7). Each item is rated on a scale from none (0) to severe (4). The AIMS total score ranges from 0 to 28. Higher values of total AIMS score indicate increased severity in abnormal movement.

Time frame:
Baseline and Day 6
Reported as:
Mean · score on a scale
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)
score on a scaleLumateperone 42 mg Once Daily for 5 Days
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)0.0 ± 0.00

Adverse events

Collected over up to 30 days after last dose, up to a total of 35 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lumateperone 42 mg Once Daily for 5 Days0/26 (0%)0/26 (0%)16/26 (61.5%)
Most frequent other events
Most frequent other events
EventLumateperone 42 mg Once Daily for 5 Days
NauseaGastrointestinal disorders7/26
HeadacheNervous system disorders6/26
VomitingGastrointestinal disorders5/26
DizzinessNervous system disorders4/26
SomnolenceNervous system disorders4/26
Orthostatic hypotensionVascular disorders3/26

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lumateperone 42 mg Once Daily for 5 Days
Mean15.2 ± 1.41
Sex: Female, Male
Sex: Female, Male(Participants)Lumateperone 42 mg Once Daily for 5 Days
Female11
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lumateperone 42 mg Once Daily for 5 Days
Hispanic or Latino0
Not Hispanic or Latino26
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lumateperone 42 mg Once Daily for 5 Days
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American26
White0
More than one race0
Unknown or Not Reported0
08

Study locations

3 sites
  • Clinical Site
    Hollywood, Florida 33024, United States
  • Clinical Site
    Atlanta, Georgia 30331, United States
  • Clinical Site
    Decatur, Georgia 30030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Jul 2022, 16 months.

Results were first posted in Nov 2025, 3 years 3 months after primary completion.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 16 months is above that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2021
First posted
Mar 3, 2021
StartActual
Mar 12, 2021
Primary completionActual
Jul 30, 2022
CompletionActual
Jul 30, 2022
Results first posted
Nov 12, 2025
Last update
Nov 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04779177
Responsible party
Sponsor
First posted
Mar 3, 2021
Start date
Mar 12, 2021
Primary completion
Jul 30, 2022
Completion
Jul 30, 2022
Results posted
Nov 12, 2025
Last update
Nov 12, 2025

Study contacts

Clinical Site
principal investigator · Atlanta, Georgia, United States, 30331
Clinical Site
principal investigator · Decatur, Georgia, United States, 30030
Clinical Site
principal investigator · Hollywood, Florida, United States, 33024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumateperone

Start the discussion